The Cell Cycle & How Cancer Hijacks It
Every cell that divides marches around the same four-stop loop: G1 grow, S copy the DNA, G2 proofread, M split in two. Between the stops sit checkpoints — quality-control gates run by cyclins and CDKs — and at the centre stands p53, the “guardian of the genome,” which halts the cycle for repair or orders self-destruct when the DNA is too broken to trust. Cancer is this machine gone rogue: the accelerator jams on and the brakes are cut. Watch the cell turn, watch a checkpoint catch damage — then break it and watch a tumour grow.
Try this: start on DNA damage and watch p53 turn amber and freeze the cycle for repair. Then switch to p53 lost — the same damage now sails through the gate and the daughters turn red with mutations.
Cell-cycle readout
What's happening
The phase names, checkpoints, cyclins, CDKs and p53 behaviour are real, and the ~24-hour clock (G1 ~11 h, S ~8 h, G2 ~4 h, M ~1 h) is a standard textbook approximation for a typical dividing human cell — real cell-cycle length varies enormously by cell type. The ring arc sizes, division speed, the integrity percentage and the cell counts are an illustrative model chosen so the mechanism is visible, not measured values.
The Science in Plain Language
Four phases, one clock
A cell that is going to divide does not just split — it works through an ordered loop called the cell cycle. In G1 (“Gap 1”) it grows and stockpiles the proteins and building blocks it will need. In S (“Synthesis”) it copies its entire genome — roughly 3.2 billion base pairs of DNA — so that each future daughter can get a complete set. In G2 it keeps growing and proofreads the fresh copy. Finally in M (“Mitosis”) the duplicated chromosomes line up and the cell physically pinches into two. For a typical dividing human cell the whole trip takes about 24 hours (roughly 11 h in G1, 8 h in S, 4 h in G2 and only about 1 h in M) — but this varies hugely: gut-lining cells race, while most mature cells sit quietly “parked” in a resting state called G0 and rarely divide at all.
Checkpoints: the quality-control gates
Between the phases sit checkpoints, and they are the reason cells almost never divide with broken DNA. Each gate asks a simple question — is the DNA intact? is the copy finished? are conditions right? — before letting the cell move on. The gates are opened by rising tides of two protein families: cyclins and the cyclin-dependent kinases (CDKs) they switch on. Cyclin D–CDK4/6 pushes the cell through early G1; cyclin E–CDK2 drives it past the G1/S restriction point (the “point of no return”); cyclin A–CDK2 runs S phase; and cyclin B–CDK1 fires the G2/M gate into mitosis. A final spindle checkpoint in M makes sure every chromosome is properly attached before they are pulled apart, so each daughter gets exactly one copy.
p53: the guardian of the genome
The master overseer is a protein called p53 (the gene is TP53). When sensors detect DNA damage, p53 levels climb fast and it does two things. First, it switches on a gene called p21, which jams the cyclin–CDK engines and freezes the cycle — buying time for repair crews to fix the DNA before it is copied or divided. Second, if the damage is too severe to fix, p53 flips the cell into apoptosis — clean, controlled self-destruction — so a dangerously mutated cell is removed rather than allowed to multiply. That double role, halt-and-repair or destroy, is why p53 earned the nickname “guardian of the genome.” Its importance shows up in the grim statistic that roughly half of all human cancers carry a broken TP53 gene.
RB and the point of no return
The other famous brake is the retinoblastoma protein (RB). In a resting cell, RB clamps down on a switch called E2F that turns on the S-phase machinery. Only when growth signals are strong and sustained do the G1 cyclin–CDKs stack enough phosphate onto RB to make it let go — releasing E2F and committing the cell, irreversibly, to divide. RB is the physical embodiment of the restriction point: a cell that has passed it will finish the cycle even if the growth signal disappears. When RB is lost or disabled, that commitment step is skipped and cells slip into division far too readily.
Cancer: gas stuck on, brakes cut
Cancer is not a single disease but a family of them, and yet nearly all of them come down to the same broken logic: the accelerator is jammed on and the brakes are cut. The stuck accelerators are oncogenes — normal growth genes like RAS and MYC that, when mutated or over-copied, scream “divide!” continuously, like a gas pedal welded to the floor. The cut brakes are tumour suppressors like p53 and RB — the very checkpoint guards, now severed like brake lines. It usually takes several such hits together: one mutation is rarely enough, which is why cancer risk climbs with age and with anything that damages DNA. With the gas on and the brakes gone, the cell divides without permission, ignores its checkpoints, and its descendants accumulate ever more mutations — a growing, disorganised mass.
Benign or malignant: why spreading is what kills
Not every runaway growth is deadly. A benign tumour divides more than it should but stays put, walled inside its original tissue — a mole or a fibroid is a lump, not a death sentence. What makes a tumour malignant — true cancer — is that its cells break out: they invade neighbouring tissue and seed new colonies in distant organs through the blood and lymph, a process called metastasis. That travelling ability, not the original lump, is what does the harm; roughly nine out of ten cancer deaths are caused by metastasis rather than the primary tumour. To spread, cancer cells acquire still more broken rules on top of the jammed cell cycle — they learn to ignore “stay in your place” signals, coax the body into growing new blood vessels to feed them, and slip past the immune cells that should recognise them as abnormal.
Why chemo and radiation cause those side effects
This same picture explains chemotherapy and radiation. Both work by battering DNA and jamming cell division — and because cancer cells divide so relentlessly, they are caught in the act more often than most tissue, tipping many of them into apoptosis. But the treatment cannot tell a tumour cell from any other fast-dividing cell. The body’s fastest-renewing normal tissues — hair follicles, the lining of the gut, and the blood-forming cells of the bone marrow — take collateral damage, which is exactly why the classic side effects are hair loss, nausea and mouth sores, and a drop in blood counts. Turn on the Chemo pulse in the animation and watch it hammer the dividing cell hardest — and notice that when p53 is lost, chemo is less able to force apoptosis, a real reason many p53-mutant tumours resist treatment.
How the clinic reads all this
The machinery in the animation is not just theory — oncologists measure it directly. A common lab test stains a tumour sample for Ki-67, a protein made only by cells that are actively in the cycle; a high Ki-67 “proliferation index” means a large fraction of the cells are dividing, which usually signals a faster-growing, higher-grade tumour. Even better, the checkpoint proteins have become drug targets. CDK4/6 inhibitors — palbociclib, ribociclib and abemaciclib — are pills that block the very cyclin D–CDK4/6 engine described above, re-imposing the G1 brake that RB normally provides. In hormone-receptor-positive breast cancer they meaningfully slow the disease and are now standard therapy, a direct clinical payoff from understanding the restriction point. It is a hopeful arc: the same broken switches that cause cancer are, one by one, becoming the handles doctors use to treat it.
An honest correction: cancer is mostly not inherited
A common fear is that a cancer gene is something you are simply born with or not. For a small number of families that is true — inherited faults in BRCA1/2, or the rare Li-Fraumeni syndrome where a broken TP53 is passed down, sharply raise lifetime risk. But this is the exception. The great majority of cancers arise from somatic mutations — damage a cell picks up during your lifetime from tobacco smoke, UV light, certain chemicals, chronic inflammation, and the ordinary copying errors that accumulate as tissues divide over decades. In other words, most p53 and RAS mutations in tumours are acquired, not inherited. That is empowering, not fatalistic: much of the DNA damage that starts the process is avoidable, and screening that catches abnormal growth early — before the brakes and accelerator are all broken — is one of the most effective tools in medicine.